You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 60 No. 9, September 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Observation
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (30)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neurology, Other
 •Nutritional and Metabolic Disorders
 •Metabolic Diseases
 •Alert me on articles by topic

Myelopolyneuropathy and Pancytopenia Due to Copper Deficiency and High Zinc Levels of Unknown Origin

Further Support for Existence of a New Zinc Overload Syndrome

Peter Hedera, MD; John K. Fink, MD; Paula L. Bockenstedt, MD; George J. Brewer, MD

Arch Neurol. 2003;60:1303-1306.

Objective  To describe a patient with idiopathic zinc overload without an identifiable source and secondary copper deficiency causing myelopolyneuropathy and pancytopenia.

Design  Case report.

Patient and Results  A 46-year-old man presented with severe bone marrow suppression and subsequently developed progressive myelopathy with sensory ataxia. No identifiable cause of myelopathy was detected, and his neuroimaging findings were unremarkable. Plasma analysis demonstrated a low copper level and an increased zinc level (<10 µg/dL [<12.6-18.9 µmol/L] and 184 µg/dL [28.2 µmol/L], respectively; normal range for both, 80-120 µg/dL [12.6-18.9 µmol/L and 12.3-18.4 µmol/L, respectively) and a low level of ceruloplasmin. There was no evidence for an external source of zinc. Daily oral supplementation with 2 mg resulted in the prompt reversal of hematologic abnormalities, improved but still subnormal plasma copper levels, and normalization of ceruloplasmin values. The patient's neurologic condition deteriorated further, with worsening of myelopathy and development of polyneuropathy. Analyses of plasma copper and zinc levels demonstrated persisting hyperzincemia and subnormal copper levels during 4 years of follow-up. Increased copper supplementation to 8 mg/d partially reversed his neurologic signs. A clinical investigation of 6 siblings and 1 surviving parent did not identify family members with similar abnormalities.

Conclusions  Persistent hyperzincemia without an identifiable external source appears to be a primary metabolic defect, while copper deficiency is a secondary phenomenon, causing hematologic and neurologic abnormalities. Two unrelated patients with similar idiopathic hyperzincemia and hypocupremia have been recently described. This suggests the existence of a new metabolic disorder with idiopathic zinc overload.


From the Departments of Neurology (Drs Hedera and Fink), Internal Medicine (Drs Bockenstedt and Brewer), and Human Genetics (Dr Brewer), University of Michigan, and the Geriatric Research Education and Clinical Center, Ann Arbor Veterans Affairs Medical Center (Dr Fink), Ann Arbor, Mich. Dr Hedera is now affiliated with the Department of Neurology, Vanderbilt University, Nashville, Tenn.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Denture cream: An unusual source of excess zinc, leading to hypocupremia and neurologic disease
Nations et al.
Neurology 2008;71:639-643.
ABSTRACT | FULL TEXT  

Hypocupremia and bone marrow failure
Haddad et al.
haematol 2008;93:e1-e5.
ABSTRACT | FULL TEXT  

Iron and Copper Toxicity in Diseases of Aging, Particularly Atherosclerosis and Alzheimer's Disease
Brewer
Exp. Biol. Med. 2007;232:323-335.
ABSTRACT | FULL TEXT  

Copper Deficiency Myeloneuropathy Resembling B12 Deficiency: Partial Resolution of MR Imaging Findings with Copper Supplementation
Goodman et al.
Am. J. Neuroradiol. 2006;27:2112-2114.
ABSTRACT | FULL TEXT  

Relapsing hypocupraemic myelopathy requiring high-dose oral copper replacement.
Prodan et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:1092-1093.
ABSTRACT | FULL TEXT  

Neuropathy progressing to myeloneuropathy 20 years after partial gastrectomy
Everett et al.
Neurology 2006;66:1451-1451.
FULL TEXT  

Copper Deficiency as Cause of Unexplained Hematologic and Neurologic Deficits in Patient with Prior Gastrointestinal Surgery
Wu et al.
J Am Board Fam Med 2006;19:191-194.
ABSTRACT | FULL TEXT  

Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation
Rowin and Lewis
J. Neurol. Neurosurg. Psychiatry 2005;76:750-751.
ABSTRACT | FULL TEXT  

Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration
Kumar et al.
Neurology 2004;63:33-39.
ABSTRACT | FULL TEXT  

Myelopathy due to copper deficiency
Prodan et al.
Neurology 2004;62:1655-1656.
FULL TEXT  

Copper Deficiency Myelopathy
Kumar et al.
Arch Neurol 2004;61:762-766.
ABSTRACT | FULL TEXT  

Myelopolyneuropathy Due to Copper Deficiency or Zinc Excess?--Reply
Hedera and Brewer
Arch Neurol 2004;61:605-605.
FULL TEXT  

Myelopolyneuropathy Due to Copper Deficiency or Zinc Excess?
Kumar and Ahlskog
Arch Neurol 2004;61:604-605.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.